Literature DB >> 30733224

Serum Metabolomic Alterations Associated with Proteinuria in CKD.

Shengyuan Luo1,2, Josef Coresh1,2,3, Adrienne Tin1,2, Casey M Rebholz1,2, Lawrence J Appel1,2,3, Jingsha Chen1,3, Ramachandran S Vasan4, Amanda H Anderson5, Harold I Feldman5,6, Paul L Kimmel7, Sushrut S Waikar8, Anna Köttgen2,9, Anne M Evans10, Andrew S Levey11, Lesley A Inker11, Mark J Sarnak11, Morgan Erika Grams12,3,13.   

Abstract

BACKGROUND AND OBJECTIVES: Data are scarce on blood metabolite associations with proteinuria, a strong risk factor for adverse kidney outcomes. We sought to investigate associations of proteinuria with serum metabolites identified using untargeted profiling in populations with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using stored serum samples from the African American Study of Kidney Disease and Hypertension (AASK; n=962) and the Modification of Diet in Renal Disease (MDRD) study (n=620), two rigorously conducted clinical trials with per-protocol measures of 24-hour proteinuria and GFR, we evaluated cross-sectional associations between urine protein-to-creatinine ratio and 637 known, nondrug metabolites, adjusting for key clinical covariables. Metabolites significantly associated with proteinuria were tested for associations with CKD progression.
RESULTS: In the AASK and the MDRD study, respectively, the median urine protein-to-creatinine ratio was 80 (interquartile range [IQR], 28-359) and 188 (IQR, 54-894) mg/g, mean age was 56 and 52 years, 39% and 38% were women, 100% and 7% were black, and median measured GFR was 48 (IQR, 35-57) and 28 (IQR, 18-39) ml/min per 1.73 m2. Linear regression identified 66 serum metabolites associated with proteinuria in one or both studies after Bonferroni correction (P<7.8×10-5), 58 of which were statistically significant in a meta-analysis (P<7.8×10-4). The metabolites with the lowest P values (P<10-27) were 4-hydroxychlorthalonil and 1,5-anhydroglucitol; all six quantified metabolites in the phosphatidylethanolamine pathway were also significant. Of the 58 metabolites associated with proteinuria, four were associated with ESKD in both the AASK and the MDRD study.
CONCLUSIONS: We identified 58 serum metabolites with cross-sectional associations with proteinuria, some of which were also associated with CKD progression. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_02_07_CJASNPodcast_19_03_.mp3.
Copyright © 2019 by the American Society of Nephrology.

Entities:  

Keywords:  AASK (African American Study of Kidney Disease and Hypertension); Cross-Sectional Studies; Diet; Linear Models; Renal Insufficiency, Chronic; chronic kidney disease; creatinine; glomerular filtration rate; hypertension; metabolism; phosphatidylethanolamine; proteinuria; risk factors

Mesh:

Substances:

Year:  2019        PMID: 30733224      PMCID: PMC6419293          DOI: 10.2215/CJN.10010818

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  32 in total

Review 1.  Metabolomics for clinical use and research in chronic kidney disease.

Authors:  Berthold Hocher; Jerzy Adamski
Journal:  Nat Rev Nephrol       Date:  2017-03-06       Impact factor: 28.314

2.  Mechanism of action and fate of the fungicide chlorothalonil (2,4,5,6-tetrachloroisophthalonitrile) in biological systems. 2. In vitro reactions.

Authors:  J W Long; M R Siegel
Journal:  Chem Biol Interact       Date:  1975-06       Impact factor: 5.192

Review 3.  Innovation: Metabolomics: the apogee of the omics trilogy.

Authors:  Gary J Patti; Oscar Yanes; Gary Siuzdak
Journal:  Nat Rev Mol Cell Biol       Date:  2012-03-22       Impact factor: 94.444

4.  Serum Levels of 1,5-Anhydroglucitol and Risk of Incident End-Stage Renal Disease.

Authors:  Casey M Rebholz; Morgan E Grams; Yuan Chen; Alden L Gross; Yingying Sang; Josef Coresh; Elizabeth Selvin
Journal:  Am J Epidemiol       Date:  2017-10-15       Impact factor: 4.897

5.  Serum concentration and renal handling of 1,5-anhydro-D-glucitol in patients with chronic renal failure.

Authors:  H Shimizu; A Shouzu; M Nishikawa; S Omoto; T Hayakawa; Y Miyake; T Yonemoto; M Inada
Journal:  Ann Clin Biochem       Date:  1999-11       Impact factor: 2.057

6.  Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome.

Authors:  J Joven; C Villabona; E Vilella; L Masana; R Albertí; M Vallés
Journal:  N Engl J Med       Date:  1990-08-30       Impact factor: 91.245

Review 7.  An overview of renal metabolomics.

Authors:  Sahir Kalim; Eugene P Rhee
Journal:  Kidney Int       Date:  2016-09-28       Impact factor: 10.612

8.  Metabolomics: beyond biomarkers and towards mechanisms.

Authors:  Caroline H Johnson; Julijana Ivanisevic; Gary Siuzdak
Journal:  Nat Rev Mol Cell Biol       Date:  2016-03-16       Impact factor: 94.444

9.  Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker.

Authors:  John B Buse; Jennifer L R Freeman; Steven V Edelman; Lois Jovanovic; Janet B McGill
Journal:  Diabetes Technol Ther       Date:  2003       Impact factor: 6.118

10.  Homeostasis of phospholipids - The level of phosphatidylethanolamine tightly adapts to changes in ethanolamine plasmalogens.

Authors:  Fabian Dorninger; Alexander Brodde; Nancy E Braverman; Ann B Moser; Wilhelm W Just; Sonja Forss-Petter; Britta Brügger; Johannes Berger
Journal:  Biochim Biophys Acta       Date:  2014-11-15
View more
  15 in total

1.  Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians.

Authors:  Farsad Afshinnia; Viji Nair; Jiahe Lin; Thekkelnaycke M Rajendiran; Tanu Soni; Jaeman Byun; Kumar Sharma; Patrice E Fort; Thomas W Gardner; Helen C Looker; Robert G Nelson; Frank C Brosius; Eva L Feldman; George Michailidis; Matthias Kretzler; Subramaniam Pennathur
Journal:  JCI Insight       Date:  2019-11-01

2.  Trans-ethnic genome-wide association study of blood metabolites in the Chronic Renal Insufficiency Cohort (CRIC) study.

Authors:  Eugene P Rhee; Aditya Surapaneni; Zihe Zheng; Linda Zhou; Diptavo Dutta; Dan E Arking; Jingning Zhang; ThuyVy Duong; Nilanjan Chatterjee; Shengyuan Luo; Pascal Schlosser; Rupal Mehta; Sushrut S Waikar; Santosh L Saraf; Tanika N Kelly; Lee L Hamm; Panduranga S Rao; Anna V Mathew; Chi-Yuan Hsu; Afshin Parsa; Ramachandran S Vasan; Paul L Kimmel; Clary B Clish; Josef Coresh; Harold I Feldman; Morgan E Grams
Journal:  Kidney Int       Date:  2022-02-01       Impact factor: 10.612

3.  Metabolic and Metabo-Clinical Signatures of Type 2 Diabetes, Obesity, Retinopathy, and Dyslipidemia.

Authors:  Noha A Yousri; Karsten Suhre; Esraa Yassin; Alya Al-Shakaki; Amal Robay; Maha Elshafei; Omar Chidiac; Steven C Hunt; Ronald G Crystal; Khalid A Fakhro
Journal:  Diabetes       Date:  2022-02-01       Impact factor: 9.461

Review 4.  Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease.

Authors:  Judy Baek; Chenchen He; Farsad Afshinnia; George Michailidis; Subramaniam Pennathur
Journal:  Nat Rev Nephrol       Date:  2021-10-06       Impact factor: 42.439

5.  Metabolite Signature of Albuminuria Involves Amino Acid Pathways in 8661 Finnish Men Without Diabetes.

Authors:  Lilian Fernandes Silva; Jagadish Vangipurapu; Ulf Smith; Markku Laakso
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

6.  Serum-Urine Matched Metabolomics for Predicting Progression of Henoch-Schonlein Purpura Nephritis.

Authors:  Qian Zhang; Ling-Yun Lai; Yuan-Yuan Cai; Ma-Jie Wang; Gaoxiang Ma; Lian-Wen Qi; Jun Xue; Feng-Qing Huang
Journal:  Front Med (Lausanne)       Date:  2021-05-12

7.  Genome-wide association study of serum metabolites in the African American Study of Kidney Disease and Hypertension.

Authors:  Shengyuan Luo; Elena V Feofanova; Adrienne Tin; Sarah Tung; Eugene P Rhee; Josef Coresh; Dan E Arking; Aditya Surapaneni; Pascal Schlosser; Yong Li; Anna Köttgen; Bing Yu; Morgan E Grams
Journal:  Kidney Int       Date:  2021-04-08       Impact factor: 18.998

8.  An untargeted metabolomics study of blood pressure: findings from the Bogalusa Heart Study.

Authors:  William J He; Changwei Li; Xuenan Mi; Mengyao Shi; Xiaoying Gu; Lydia A Bazzano; Alexander C Razavi; Jovia L Nierenberg; Kirsten Dorans; Hua He; Tanika N Kelly
Journal:  J Hypertens       Date:  2020-07       Impact factor: 4.844

9.  NAT8 Variants, N-Acetylated Amino Acids, and Progression of CKD.

Authors:  Shengyuan Luo; Aditya Surapaneni; Zihe Zheng; Eugene P Rhee; Josef Coresh; Adriana M Hung; Girish N Nadkarni; Bing Yu; Eric Boerwinkle; Adrienne Tin; Dan E Arking; Inga Steinbrenner; Pascal Schlosser; Anna Köttgen; Morgan E Grams
Journal:  Clin J Am Soc Nephrol       Date:  2020-12-31       Impact factor: 8.237

10.  Metabolite Biomarkers of CKD Progression in Children.

Authors:  Michelle R Denburg; Yunwen Xu; Alison G Abraham; Josef Coresh; Jingsha Chen; Morgan E Grams; Harold I Feldman; Paul L Kimmel; Casey M Rebholz; Eugene P Rhee; Ramachandran S Vasan; Bradley A Warady; Susan L Furth
Journal:  Clin J Am Soc Nephrol       Date:  2021-08       Impact factor: 10.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.